ClusterInfo

Verapamil basics

How verapamil works for cluster headaches, the correct dose, who should not take it, and the most common side effects.

Last updated: June 2026

Verapamil is a heart medication that cluster headache patients take to reduce the frequency of their attacks. Many patients report a significant decrease in attacks 1 to 2 weeks after starting to take it, and it is relatively safe to take if you don't have a heart condition. It is the most commonly prescribed preventive medication for cluster headaches, and it has been used for about 40 years. This chapter explains what verapamil is, why it works, what dose to aim for, and how to think about its effectiveness and side effects.

What is verapamil?

Verapamil is a heart medication. It was first approved in the US in 1981 for high blood pressure, angina (chest pain from narrowed coronary arteries), and certain abnormal heart rhythms.[1] It belongs to a family called calcium channel blockers.

As the name suggests, verapamil blocks calcium from entering the cells in the heart and in the walls of blood vessels. Since calcium triggers cells to contract, verapamil causes blood vessels to be more relaxed and less excitable.[2] We don't yet know exactly why this mechanism helps prevent cluster headaches.

Despite being widely used, verapamil is off-label for cluster headache everywhere in the world,[3][4] which means that no regulator has formally approved it for cluster headache, but every major headache guideline still recommends it as the first-line preventive.[5][4] In 2025, the World Health Organization added verapamil to its "Model List of Essential Medicines" specifically for cluster headache, alongside prednisolone and injectable sumatriptan.[6]

Why does verapamil work for cluster headache?

Despite having been used to treat cluster headaches for about four decades, we don't yet know exactly why verapamil prevents attacks (as suggested by Petersen and colleagues' 2019 paper "Verapamil and cluster headache: still a mystery").[7]

Peng and Burish suggest that verapamil may have multiple mechanisms of action.[8] For instance, we know that verapamil also acts on calcium channels in the hypothalamus, a brain region responsible for various circadian rhythm functions. The hypothalamus plays a key role in the timing of cluster headache attacks. Verapamil also affects calcium channels in the trigeminal nerve, which is the main nerve behind the eye that gets hyperactivated during a cluster headache attack. The drug also interacts with serotonin, noradrenaline, dopamine, and other systems that may contribute to attacks.[1]

What is the correct dose of verapamil for cluster headache?

For heart conditions, verapamil is typically dosed at 120 to 360 mg per day, but that's too low for cluster headaches. When taken to prevent cluster headaches, one typically takes 360 to 720 mg per day, and some patients need 960 to 1,200 mg per day or more.[1][9][10] Pharmacists are sometimes surprised by these doses and have to phone the prescriber to double-check the prescription. Primary-care doctors who have never treated cluster headache before sometimes refuse to go higher than the heart dose.

The reason for such a high dose is that verapamil has a much harder time getting into the brain than into the heart. The brain's blood vessels have pumps that actively push verapamil back out into the bloodstream before it can reach the hypothalamus and trigeminal nerve.[11][12][1] To overcome this, blood levels have to be much higher than what's needed for heart conditions, which is why cluster headache doses look excessive compared to cardiology doses.

How effective is verapamil for cluster headache?

For being a first-line treatment, the scientific literature on verapamil is somewhat thin, but here's what we know.

There has only been one placebo-controlled randomized trial of verapamil for cluster headache. In 2000, Leone and colleagues randomized 30 patients with episodic cluster headache to verapamil 360 mg/day or placebo for 14 days. By the end of the trial, 80% of the verapamil group saw at least a 50% reduction in attacks, compared with 0% on placebo, and about 27% became completely attack-free.[13] Note that the dose used (360 mg/day) is at the low end of what is now common in practice.

In addition to the RCT above, the largest open-label series tested individualized dosing in 70 patients.[10] With careful titration, 94% of episodic patients and 55% of chronic patients reached complete relief. Most patients settled between 200 and 480 mg/day; a smaller group needed 520 to 960 mg/day. In an earlier open-label series of 48 patients, 69% of patients saw a >75% improvement, with no significant difference between episodic and chronic responders.[14]

Patient surveys paint a more mixed picture. A systematic review of survey studies by Rusanen and colleagues found that only about 50% of patients who had tried verapamil reported a positive response, which is lower than the clinical studies.[15] This probably reflects a mix of issues: under-dosing (most patients never reach sufficiently high doses), patients stopping the drug because of side effects, and the natural difficulty of judging a preventive when cluster cycles also end on their own.

The 2010 American Academy of Neurology guideline rated verapamil as Level C, meaning "possibly effective," reflecting that small evidence base; the 2023 European Academy of Neurology guideline still gives it a strong recommendation, reflecting that no other oral preventive has done better in head-to-head comparisons.[16][4]

How long does it take for verapamil to work?

You should expect about 1 to 2 weeks (assuming the dosage is correct) before noticing a significant reduction in attack frequency, and 2 to 3 weeks to reach its full effect.[4][17] Because verapamil is slow to take effect, and because you have to titrate up step by step rather than start at the full dose, many doctors prescribe a short course of prednisone or a greater occipital nerve block to bridge the first two or three weeks while the verapamil dose is increased. These bridge treatments are covered in our bridge treatments chapter.

The dose matters more than the time. The most common reason patients abandon verapamil is because they stay at a dose that isn't high enough to do anything for cluster headache (for example, 40 to 120 mg/day).[1] As Bob Wold of Clusterbusters puts it, most failures are dose failures, not drug failures.[18]

Who can take verapamil, and who should avoid it?

Verapamil is the standard first-line preventive for both episodic and chronic cluster headache patients. If you've been newly diagnosed, your neurologist or headache specialist will almost certainly suggest it.

You should not take verapamil if you have any of the following:[3][2]

  • A second- or third-degree heart block, without a pacemaker.
  • Sick sinus syndrome, without a pacemaker.
  • Severe heart failure or a heart pumping at less than 30% of normal capacity.
  • Very low blood pressure (systolic below 90 mmHg) or cardiogenic shock.
  • A specific arrhythmia called Wolff-Parkinson-White syndrome with atrial fibrillation or flutter. In this combination, verapamil can trigger a life-threatening rhythm.

Talk to your doctor first if you have:

  • Any other heart condition or a history of heart problems.
  • Liver or kidney disease.
  • Severely low blood pressure at baseline.
  • You're pregnant or planning to be (verapamil is generally considered acceptable in pregnancy for cluster headache, but the high doses used haven't been formally studied).[19]
  • You take any medication that interacts with verapamil. The biggest ones are beta-blockers, digoxin, certain statins (simvastatin, lovastatin), grapefruit juice, and several antibiotics. The full list is on the safety page.

To manage expectations, keep in mind that about half of chronic cluster headache patients on adequate doses get substantial relief, and maybe 1 in 5 to 1 in 4 become completely free of attacks.[10] Many patients tolerate the side effects (constipation, fatigue, a slower pulse, sometimes peripheral swelling) because the alternative is worse. A meaningful minority finds verapamil doesn't work for them at any dose, and other options exist if that's you. See our preventive treatments guide.

What are the side effects of verapamil?

Here are some side effects you may notice during titration or at high doses:

  • Constipation. The most common side effect, reported by 7 to 25% of patients and more often at doses above 480 mg/day.[20] The Clusterbusters Pocket Guide recommends 400 mg/day of magnesium to counter it, alongside fiber and hydration.[18]
  • Fatigue or reduced stamina. Around 6% of patients report feeling slow or getting easily tired;[21] patient reports suggest it's more common in real-world use.
  • Slow pulse and lightheadedness on standing. Verapamil slows the heart rate. About a third of cluster headache patients on verapamil have a resting heart rate below 60 beats per minute, and you may feel a bit dizzy when standing up quickly, especially while the dose is going up.[22]
  • Swollen ankles and feet. This is caused by widening of the small blood vessels, not by fluid retention, so diuretics don't help. Mild cases settle, while severe swelling means the dose might be too high.
  • Gum overgrowth. About 4% of patients on verapamil for more than a year develop thickened gums.[23] It reverses when the drug is stopped or reduced.
  • Worsening of migraines in patients who also have migraine.[21]

References

  1. ↩ Tfelt-Hansen P, Tfelt-Hansen J (2009). Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache, 49(1), 117–125. doi:10.1111/j.1526-4610.2008.01298.x
  2. ↩ Aboumrad MJ, Shumway K (2024). Verapamil. StatPearls. Link
  3. ↩ U.S. Food and Drug Administration (2011). Verelan (verapamil hydrochloride) prescribing information. FDA. Link
  4. ↩ May A, Evers S, Goadsby PJ, Leone M, Manzoni GC, Pascual J, et al. (2023). European Academy of Neurology guidelines on the treatment of cluster headache. European Journal of Neurology, 30(10), 2955–2979. doi:10.1111/ene.15956
  5. ↩ Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ (2016). Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines. Headache, 56(7), 1093–1106. doi:10.1111/head.12866
  6. ↩ Tassorelli C, Lampl C, García-Azorín D, et al. (2026). WHO Model List of Essential Medicines additions for cluster headache. Cephalalgia. Link
  7. ↩ Petersen AS, Barloese MCJ, Snoer A, Soerensen AMS, Jensen RH (2019). Verapamil and cluster headache: still a mystery. A narrative review of efficacy, mechanisms and perspectives. Headache, 59(8), 1198–1211. doi:10.1111/head.13603
  8. ↩ Peng KP, Burish MJ (2023). Management of cluster headache: treatments and their mechanisms. Cephalalgia. Link
  9. ↩ Lantéri-Minet M, Silhol F, Piano V, Donnet A (2011). Cardiac safety in cluster headache patients using the very high dose of verapamil (≥720 mg/day). Journal of Headache and Pain, 12(2), 173–178. doi:10.1007/s10194-010-0289-x
  10. ↩ Blau JN, Engel HO (2004). Individualizing treatment with verapamil for cluster headache patients. Headache, 44(10), 1013–1018. Link
  11. ↩ Saaby L, Tfelt-Hansen P, Brodin B (2015). The putative P-gp inhibitor telmisartan does not affect the transcellular permeability and cellular uptake of the calcium channel antagonist verapamil in the polarised epithelial cell lines MDCK, MDCK-MDR1 and Caco-2. Pharmacology Research & Perspectives. doi:10.1002/prp2.151
  12. ↩ Hougaard A, Tfelt-Hansen P (2014). Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists. Journal of Headache and Pain, 15(Suppl 1), G19. Link
  13. ↩ Leone M, D'Amico D, Frediani F, et al. (2000). Verapamil in the prophylaxis of episodic cluster headache: a double-blind study versus placebo. Neurology, 54(6), 1382–1385. Link
  14. ↩ Gabai IJ, Spierings ELH (1989). Prophylactic treatment of cluster headache with verapamil. Headache, 29(3), 167–168. Link
  15. ↩ Rusanen SS, De S, Schindler EAD, Artto VA, Storvik M (2022). Self-reported efficacy of treatments in cluster headache: a systematic review of survey studies. Current Pain and Headache Reports, 26(8), 623–637. Link
  16. ↩ Francis GJ, Becker WJ, Pringsheim TM (2010). Acute and preventive pharmacologic treatment of cluster headache. Neurology, 75(5), 463–473. Link
  17. ↩ Practical Neurology editorial staff (2023). Cluster headache preventive therapies. Practical Neurology. Link
  18. ↩ Wold B (2025). Pocket Guide to Cluster Headaches (Complete Handbook 1.5). Clusterbusters. Link
  19. ↩ Jürgens TP, Schaefer C, May A (2009). Treatment of cluster headache in pregnancy and lactation. Cephalalgia, 29(4), 391–400. Link
  20. ↩ Drugs.com (2024). Verapamil side effects. Drugs.com. Link
  21. ↩ Wilcha R-J, Goadsby PJ (2024). Verapamil in patients with cluster headache with concurrent migraine. Cephalalgia Reports.
  22. ↩ Cohen AS, Matharu MS, Goadsby PJ (2007). Electrocardiographic abnormalities in patients with cluster headache on verapamil therapy. Neurology, 69(7), 668–675. Link
  23. ↩ Mehrotra V, Sirbu D, Hsu CC, Goadsby PJ (2004). Verapamil-induced gingival enlargement in cluster headache. British Dental Journal. Link

Did you find this page helpful?

Disclaimer

The information on this website is provided for educational and harm reduction purposes only. It does not constitute medical advice and should not replace consultation with a qualified healthcare professional. See our Legal page for more details.